Q1 FY26 revenue declined 5% year-over-year to INR 204 crore due to sales lumpiness, with EBITDA and PAT impacted by startup costs at the new injectable facility. Formulation revenue grew 12%, API declined 10%, and the company advanced its US and India market presence, CDMO, and injectables ramp-up.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.